Our team of life science professionals has extensive experience in discovering and developing treatments for cardiometabolic diseases, including obesity and diabetes. Our mission is to target multiple disease-causing mechanisms through innovative mAb-peptide-based polyfunctional products. With a vision to provide a new generation of user-friendly solutions, we are dedicated to delivering lasting benefits for people living with obesity and associated cardiometabolic conditions.

Obesity and overweight are increasingly being recognized as a health issue of epidemic proportions, impacting over 1 billion patients worldwide and associated with a growing list of comorbidities. Thanks to medical and pharmaceutical innovation, a new class of weight loss agents has emerged – the GLP-1 receptor agonists (GLP1 RA)- GLP1 Ras are believed to act by promoting satiety and helping with weight management.

At SixPeaks Bio we believe that protection of lean tissue mass will be a core component for future healthy weight management solutions. We are targeting preservation and potentially an expansion of skeletal muscle mass as a future therapeutic companion to GLP1 RAs.